Canada markets open in 6 hours 43 minutes
  • S&P/TSX

    21,212.39
    +24.20 (+0.11%)
     
  • S&P 500

    4,549.78
    +13.59 (+0.30%)
     
  • DOW

    35,603.08
    -6.26 (-0.02%)
     
  • CAD/USD

    0.8099
    +0.0015 (+0.18%)
     
  • CRUDE OIL

    82.02
    -0.48 (-0.58%)
     
  • BTC-CAD

    77,384.39
    -2,407.24 (-3.02%)
     
  • CMC Crypto 200

    1,491.40
    -43.25 (-2.82%)
     
  • GOLD FUTURES

    1,791.60
    +9.70 (+0.54%)
     
  • RUSSELL 2000

    2,296.18
    +6.42 (+0.28%)
     
  • 10-Yr Bond

    1.6760
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,398.50
    -80.25 (-0.52%)
     
  • VOLATILITY

    15.01
    -0.48 (-3.10%)
     
  • FTSE

    7,190.30
    -32.80 (-0.45%)
     
  • NIKKEI 225

    28,804.85
    +96.27 (+0.34%)
     
  • CAD/EUR

    0.6959
    +0.0007 (+0.10%)
     

Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DURHAM, N.C., September 10, 2021--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 13-15, 2021.

The pre-recorded presentation will be made available for on-demand viewing starting Monday, September 13, 2021 at 7:00 a.m. ET on the Company’s website, www.precisionbiosciences.com, in the Investors & Media section under Events and Presentations. An archived replay of the webcast will be available for approximately 90 days.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210910005202/en/

Contacts

Investor Contact:
Alex Kelly
Chief Financial Officer
Alex.Kelly@precisionbiosciences.com

Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting